The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sangamo Therapeutics Inc

Nasdaq: SGMO
Last

(U.S.) $3.95

Today's change-0.15 -3.66%
Updated January 19 4:00 PM EST. Delayed by at least 15 minutes.
 

Sangamo Therapeutics Inc

Nasdaq: SGMO
Last

(U.S.) $3.95

Today's change-0.15 -3.66%
Updated January 19 4:00 PM EST. Delayed by at least 15 minutes.

Sangamo Therapeutics Inc down (U.S.)$0.15

Sangamo Therapeutics Inc closed sharply lower Thursday, dropping (U.S.)$0.15 or 3.66% to (U.S.)$3.95. Over the last five days, shares are unchanged, but down 33.95% for the last 52 weeks. This security has underperformed the S&P 500 by 54.27% during the last year.

Key company metrics

  • Open(U.S.) $4.15
  • Previous close(U.S.) $4.10
  • High(U.S.) $4.15
  • Low(U.S.) $3.77
  • Bid / Ask(U.S.) $3.25 / (U.S.) $4.10
  • YTD % change+29.51%
  • Volume1,696,307
  • Average volume (10-day)1,084,248
  • Average volume (1-month)1,074,007
  • Average volume (3-month)957,231
  • 52-week range(U.S.) $2.65 to (U.S.) $7.60
  • Beta3.24
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.08
Updated January 19 4:00 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue3449
Total other revenue--------
Total revenue3449
Gross profit--------
Total cost of revenue--------
Total operating expense22312125
Selling / general / administrative51155
Research & development17191520
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-19-27-17-16
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-19-27-16-16
Income after tax-19-27-16-14
Income tax, total000-2
Net income-19-27-16-14
Total adjustments to net income--------
Net income before extra. items-19-27-16-14
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-19-27-16-14
Inc. avail. to common incl. extra. items-19-27-16-14
Diluted net income-19-27-16-14
Dilution adjustment--------
Diluted weighted average shares71707070
Diluted EPS excluding extraordinary itemsvalue per share-0.27-0.38-0.23-0.20
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.27-0.38-0.23-0.20